From: Clinical and pathological predictors of relapse in IgG4-related disease
 | All patients (n = 68) | Patients in remission (n = 47) | Patients with relapse (n = 21) | p |
---|---|---|---|---|
Age (years) | 57 (47–63) | 57.5 (46.8–64.0) | 55.5 (41.3–62.8) | 0.660* |
Sex (male) | 51 (75) | 35 (74) | 16 (76) | 0.880** |
Time from onset of symptoms to diagnosis (months) | 7 (2–23) | 6 (1–20) | 12 (5–27) | 0.081* |
Organ involvement | ||||
 ≥2 | 40 (58.8) | 24 (51.1) | 16 (76.2) | 0.045** |
 ≥3 | 23 (33.8) | 13 (27.7) | 10 (47.6) | 0.112** |
Head and neck involvement | 24 (35.3) | 17 (36.2) | 7 (33.3) | 0.821** |
Visceral organ involvement | 46 (67.6) | 32 (68.1) | 14 (66.7) | 0.908** |
Allergy history | 14 (23.3) | 9 (21.95) | 5 (26.3) | 0.710** |
IgG4-RD RI | 9 (6–12) | 6 (6–12) | 9 (6–12) | 0.038* |
Serum IgG4 (g/L) | 3.90 (1.44–10.19) | 3.09 (1.12–7.26) | 7.26 (2.68–18.85) | 0.026* |
E (%) | 2.05 (0.50–4.25) | 2.7 (1.1–4.8) | 1.5 (0.4–2.2) | 0.074* |
ESR (mm/h) | 41 (12–83) | 41 (13–82) | 42 (10–92) | 0.783* |
CRP (mg/L) | 6.1 (0.8–31.5) | 6.8 (0.73–28.0) | 4.97 (0.55–50.2) | 0.955* |
Serum IgG (g/L) | 16.7 (11.5–22.9) | 14.4 (10.9–20.3) | 19.9 (15.5–34.3) | 0.011* |
Serum IgE (IU/mL) | 112 (24–294) | 112 (22–260) | 119 (25–313) | 0.831* |
C3 (g/L) | 0.99 (0.80–1.18) | 1.02 (0.81–1.21) | 0.92 (0.72–1.15) | 0.196* |
C4 (g/L) | 0.19 (0.13–0.26) | 0.23 (0.15–0.27) | 0.16 (0.07–0.21) | 0.019* |
TG (mmol/L) | 1.12 (0.82–1.83) | 1.15 (0.94–1.87) | 0.90 (0.71–1.54) | 0.046* |
TC (mmol/L) | 3.71 (3.38-4.52) | 4.18 (3.56–4.91) | 3.38 (2.82–3.72) | 0.005* |
LDL (mmol/L) | 2.20 (1.73-2.64) | 2.50 (1.98–2.99) | 1.92 (1.61–2.27) | 0.030* |